Brief: Akari Therapeutics Granted 180-Day Extension By Nasdaq To Meet Minimum Bid Price Requirement
25/04/2023 22:12
Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS GRANTED 180-DAY EXTENSION BY NASDAQ TO
MEET
MINIMUM BID PRICE REQUIREMENT
Source text for Eikon: ID:nGNEc1SW7p
Further company coverage: AKTX.O
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics